Approach

We are developing therapies that target muscle tissue with unprecedented precision to restore muscle health. The company’s FORCE™ platform can deliver oligonucleotides and other molecules to skeletal, cardiac and smooth muscle to treat a range of serious muscle diseases. In addition to Dyne’s initial focus on myotonic dystrophy type 1 (DM1), we are advancing additional programs in Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
